• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » Scientific Evidence » Congress Publications

Congress Publications

The following is a list of scientific abstracts, posters and presentations on our research using the microbiota-based products currently under development in the MRT™ drug platform. Click on the title of the congress publication below to view complete details.

Researching the Potential of the Microbiome and Investigational Microbiota-Based Therapeutics

Microbiota and Microbiota Restoration for Recurrent C. diff Infections

2022 National C. diff Advocacy Summit
May 1 – 2, 2022, Washington, D.C.

Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial

Infectious Diseases Week (ID Week)
September 29 – October 3, 2021, Virtual Event

Antimicrobial Resistance Genes were Reduced Following Administration of Investigational Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection

Infectious Diseases Week (ID Week)
September 29 – October 3, 2021, Virtual Event

Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data From Five Prospective Clinical Studies

Infectious Diseases Week (ID Week)
September 29 – October 3, 2021, Virtual Event

Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial

Infectious Diseases Week (ID Week)
September 29 – October 3, 2021, Virtual Event

Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies

Infectious Diseases Week (ID Week)
September 29 – October 3, 2021, Virtual Event

Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-Based Therapeutic RBX2660 For Recurrent Clostrioides difficile Infection

Infectious Diseases Week (ID Week)
October 21 – October 25, 2020, Virtual Event

Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-Based Therapeutic RBX7455 to Individuals with Recurrent Clostrioides difficile Infection

Infectious Diseases Week (ID Week)
October 21 – October 25, 2020, Virtual Event

Prevention of Recurrent Clostridioides difficile Infection at Two Years After Treatment with Investigational Microbiota-Based Drug RBX2660:  Efficacy, Durability, Microbiome Changes, and Participant Demographics of a Phase 2 Open-Label Clinical Trial  

World Congress of Gastroenterology @ ACG 2020
October 23-28, 2020, Nashville, TN

Improvement of MICROBIOME HEALTH INDEX™ in Patients with Recurrent Clostridiodes difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes

ASM Microbe 2019
June 20-24, 2019, San Francisco, CA

Response to Microbiota-Based Drug RBX2660 is Associated with Reduction in Antimicrobial Resistance Genes in Patients with Recurrent Clostridiodes difficile Infections

ASM Microbe 2019
June 20-24, 2019, San Francisco, CA

RBX7455 – A Non-frozen, Lyophilized, Oral Microbiota-based Drug Reduces Clostridrium difficile Infection Recurrence and Restores Patients’ Microbiomes

ACG 2018
October 5-10, 2018, Philadelphia, PA

Prevention of Recurrent Clostridium difficile at Six Months Following Treatment with Microbiota-based Therapy RBX2660: Durability Results From a Phase 2 Open-label Study

IDWeek 2018
October 3-7, 2018, San Francisco, CA

Evaluating a Prototype MICROBIOME HEALTH INDEX™ (MHI™) as a Measure of Microbiome Restoration Using Data Derived From Published Studies of Fecal Microbiota Transplant to Treat recurrent Clostridium difficile Infections (rCDI)

IDWeek 2018
October 3-7, 2018, San Francisco, CA

A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455

ASM Microbe 2018
June 7-11, 2018, Atlanta, GA

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™

Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC

A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome

Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC

The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials

28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation of a Prototype MICROBIOME HEALTH INDEX™

28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain

Altering the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficileInfections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

There is No Association Between Patient Outcomes and Demographics in an Open-Label Safety and Efficacy Study of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Resetting the Microbial Landscape: Donor Microbiome Engraftment in Patients Treated with RBX2660 for Multi-Recurrent Clostridium difficile Infection

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Meta-analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-based Drug for Recurrent Clostridium difficile Infection

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trial

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Does the Donor Matter? Results from PUNCH CD 2, a Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results of the PUNCH CD 2 Trial

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Placebo Responders in a Randomised Controlled Trial of RBX2660 for Recurrent C. Difficile Infection: Predictive Value of 16s rRNA Microbiome Analysis

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

Increased Microbial Diversity Found in Successful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection

Gut Microbiota for World Health
March 5-6, 2016, Miami, FL

Infectious Threats in “Healthy” Donors: Results of a Donor Screening Program for a Next-Generation FMT

Gut Microbiota for World Health
March 5-6, 2016, Miami, FL

Increased Microbial Diversity Found in Successful vs. Unsuccessful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection

Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA

Assessing Infectious Threats in “Healthy” FMT Donors: Results of an Assessment Program to Support a Next-Generation Drug for Recurrent Clostridium difficile Infection

Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA

Successful Implementation of a Phase 2 Study of a Novel Microbiota-based Drug for Recurrent Clostridium difficile Infection

Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD

Perspectives on the PUNCH CD Trial of a Microbiota-Based Drug Targeted at Recurrent C. difficile Infection

Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD

Does the Donor Matter? Donor vs. Patient Effects in the Outcome of Next-Generation Fecal Transplant for Recurrent Clostridium difficile Infection

Digestive Diseases Week
May 16–19, 2015, Washington, DC

Clearance of Vancomycin-Resistant Enterococcus Concomitant with Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection

European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark

Results of the Phase 2 PUNCH™ CD Safety Study of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark

Enema Administration of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: Lessons Learned from the PUNCH CD Study

American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA

Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

American College of Gastroenterology
October 8-12, 2014, Philadelphia, PA

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH™ CD Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Regulatory Considerations in Commercializing a Non-Antibiotic Microbiota-Based Drug Targeted for Recurrent Clostridium difficile Infection

Microbiome / Microbiota
R&D and Business Collaboration Forum
October 2-3, 2014, San Diego, CA

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us